Company
Immunocore
Pioneers of the world’s first TCR therapy
Also known as Immunocore Ltd
- Status
- Operatingas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Immunocore Ltd
- immunocore.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy.
Funding snapshot
- Total raised
- $140MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $140M2022-07-20
Funding rounds
- Round, 2022
- $140M2022-07-20, SEC form D sold, 8 investors
Products
- Other
- KIMMTRAK (tebentafusp)
Loading relationship preview